I nsulin resistance (IR) is the central feature of type 2 diabetes mellitus (T2D) and represents a major complication, commonly associated with atherogenic dyslipidemia. The latter is characterized by hypertriglyceridemia, elevated plasma very-low-density lipoprotein, reduced high-density lipoprotein (HDL), and presence of small, dense low-density lipoprotein (LDL). 1 This atherogenic dyslipidemia is increasingly recognized as a postprandial phenomenon, 2 because postprandial triglyceride-rich lipoproteins (TRLs) and chylomicron remnants have been implicated as significant risk factors for atherosclerosis. 3-5 Exaggerated hepatic very-low-density lipoprotein production and impaired plasma triglyceride clearance are thought to play a key role in this disorder. However, mounting evidence underlines the active implication of the small intestine in postprandial lipid alterations.
dominant role of hepatic and intestinal TRL overproduction in dyslipidemia in both fasting and fed states. [6] [7] [8] [10] [11] [12] [13] [14] [15] For example, dyslipidemia in insulin-resistant Psammomys obesus is associated with hepatic overproduction of triglyceride-rich very-low-density lipoprotein and with intestinal overproduction of chylomicrons. [6] [7] [8] Insulin-resistant animals were also characterized by a dysfunctional intestinal and hepatic cholesterol homeostasis. 16 Only few studies have confronted the relevant issue of these important findings to humans as did the pioneering work of Lewis' group, using stable isotope tracer infusion. [17] [18] [19] They have shown an association between the increase in apolipoprotein (Apo) B-48-containing lipoproteins and IR in humans. 17, 18 Nevertheless, the link between this exaggerated assembly and secretion of TLR and in situ IR in the gut is not yet fully understood.
Obesity has been proposed to predate and promote IR molecular defect(s) although this assumption has seldom been proven in human and was not addressed in the small intestine. Evidently, caution should be exercised when extrapolating results from experimental animal models because of differences among species. This is reinforced in view of the distinct intestinal response to insulin sensitization in humans, which could differ from that in animals. 15 Therefore, an important question to address is whether the small intestine of obese individuals with systemic IR is endowed with impaired insulin responsiveness/signaling. Moreover, it is crucial to determine whether the mechanisms include oxidative stress and inflammation. Finally, efforts are necessary to explore whether these pathophysiological conditions trigger Apo B-48-containing lipoprotein overproduction in the small intestine of obese subjects.
The opportunity to obtain intestinal specimens from insulin-sensitive and insulin-resistant obese subjects allowed us to test the hypothesis that subjects with systemic IR display poor intestinal insulin sensitivity attributable to cellular and molecular defects in insulin signaling cascade, which are promoted by local oxidative stress and inflammation. As a result, abnormally high lipogenesis and lipoprotein production develops in the enterocyte.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Subjects and Tissue Sampling
Twenty subjects (10 women and 10 men) undergoing biliopancreatic diversion were assigned to 2 groups matched for age, sex, and body mass index (BMI), but with either relatively low (<3) or high (>7) IR according to their homeostasis model assessment of insulin resistance (HOMA-IR). Overnight fasting blood samples were drawn on the morning before surgery to assess lipid profile and glucose homeostasis. Duodenum specimens were obtained during the surgery. The intestinal samples were immediately transferred to the laboratory for intestinal organ culture to perform functional studies (eg, de novo lipogenesis, Apo B-48 biogenesis, and chylomicron assembly and secretion). The remaining tissue was immediately frozen in liquid nitrogen and stored at -80°C for subsequent oxidative stress and inflammation analyses.
Results

Anthropometric and Metabolic Characteristics
As per our study design, all patients were obese and candidates for bariatric surgery, which allowed us to obtained the specimens of proximal intestine. Baseline characteristics of the subjects are listed in Table 1 . Overall, the mean age was 42.6 years and the cohort had 50% men. The mean BMI was 53.8 kg/m 2 with a large range (42.6-65.2 kg/m 2 ). The subjects were divided into 2 paired groups according to their HOMA-IR index. Although there were no differences in age, sex, and BMI between insulin-sensitive and insulin-resistant groups, an increase was evidenced in fasting insulin levels and HOMA-IR index, as well as in glycohemoglobin values in the insulin-resistant group. Table 2 shows the detailed lipid profile of insulin-sensitive and insulin-resistant subjects. Insulin-resistant subjects present higher triglyceride levels and lower HDL-cholesterol concentrations as compared with insulin-sensitive subjects. In view of their low HDL-cholesterol, insulin-resistant subjects display higher total cholesterol to HDL-cholesterol ratio, which suggests an increased risk of CVD. Total and LDL cholesterol concentrations were not significantly different between the 2 groups, but LDL particles were smaller. On the other hand, no significant differences were observed in plasma free cholesterol, cholesterol ester, and phospholipids between the 2 groups.
Intestinal Insulin Signaling
We first assessed phosphorylation of insulin signaling molecules in the intestine of obese subjects. Basal Ser473 phosphorylation of protein kinase B was reduced in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 1A ). This finding was accompanied with an increase in Thr180/Tyr182 phosphorylation of p38 mitogen-activated protein kinase involved in the signal transduction of stress and inflammatory cytokines in several metabolic pathways ( Figure 1B) . These observations suggest that systemic IR is associated with alterations in intracellular signaling of insulin and cytokines involved in key intestinal metabolic process.
Intestinal Oxidative Stress Markers
The presence of oxidative stress in the intestine of insulin-resistant subjects was assessed using biomarkers of lipid peroxidation. Using HPLC, we noted higher levels of
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ATP-binding cassette A1 transporter malondyaldehyde, a byproduct of polyunsaturated fatty acid peroxidation, in the intestine of insulin-resistant compared with insulin-sensitive subjects (Figure 2A) . Similarly, spectrophotometric analyses of the intestine of insulin-resistant subjects showed an increase in conjugated dienes, which are generally generated after polyunsaturated fatty acid peroxidation ( Figure 2B ). Additionally, the exposure of freshly obtained intestine to iron/ascorbate-mediated lipid peroxidation conditions consistently promoted a higher production of conjugated dienes in the intestine of insulin-resistant subjects ( Figure 2B ). This increased generation of lipid peroxidation by products (ie, malondyaldehyde and conjugated dienes) may find its origin in a reduced intestinal antioxidant protection. In this perspective, we assessed superoxide dismutase, a key antioxidant enzyme, and observed a lower activity in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 2C ). However, no significant changes were observed in the activity of other antioxidant enzymes such as catalase ( Figure 2D ) and glutathione peroxidase ( Figure 2E ). A decreased superoxide dismutase activity may suggest a failure to properly protect the intestine against the negative impact of endogenous oxygen-free radicals and exogenous pro-oxidant conditions.
Intestinal Inflammatory Markers
Because low-grade inflammation is causative of IR, we determined the status of inflammatory markers in the intestine of insulin-resistant and insulin-sensitive subjects. Intercellular adhesion molecule-1 levels were higher in the intestinal samples of insulin-resistant subjects ( Figure 3A) . A rise in the concentrations of interleukin-6 was also found in the culture media of intestinal explants of insulin-resistant subjects ( Figure 3B ). Moreover, the addition of proinflammatory lipopolysaccharides to the organ culture further induced interleukin-6 secretion, and this phenomenon was significantly greater in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 3B ). Furthermore, the analysis of tumor necrosis factor-α revealed a rise in gene and protein expression although the latter reached a lesser statistical significance (P<0.06; Figure 2C and 2D). In addition, cyclooxygenase 2 protein content was significantly higher in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 2E ). Because most of the aforementioned inflammatory factors are activated by nuclear factor-κB (NF-κB), the transcription factor that initiates and amplifies inflammation, we finally assessed the activation of this pathway. We noticed a slight but non significant increase in NF-κB protein content, but the NF-κB to inhibitor of κB ratio, an indicator of NF-κB pathway activation, was significantly increased ( Figure 2F ). No significant change was observed in c-Jun N-terminal kinases pathway activation as well as in Toll-like receptor 4 and interleukin-1β gene expression between the intestinal samples of both groups of subjects (data not shown). These data suggest that the intestine of insulin-resistant subjects is more prone to develop a chronic low-grade inflammation state compared with the intestine of insulin-sensitive subjects.
Intestinal De Novo Lipogenesis, Apo B-48 Biogenesis, and Lipoprotein Production
To verify the impact of IR, oxidative stress, and inflammation on intestinal lipid metabolism, we measured de novo lipogenesis rate, Apo B-48 biogenesis, and TRL production. We found a significantly reduced intestinal Thr172 phosphorylation of 5′-adenosine monophosphate-activated protein kinase, which is indicative of its inactivation in insulin-resistant subjects ( Figure 4A ). In addition, Ser79 phosphorylation of acetyl-CoA carboxylase, a key downstream effector of 5′-adenosine monophosphate-activated protein kinase regulating lipid synthesis, was also reduced Fresh intestinal explants were incubated in the presence or absence of 100 μg/mL lipopolysaccharide (LPS) for 6 h. mRNA expression of tumor necrosis factor-α (TNF-α) gene was assessed by quantitative RT-PCR (C). The relative mRNA foldchanges between groups were calculated using the 2 −ΔΔCt method. The results were normalized to ATP5O mRNA expression. Tissue homogenates were also analyzed by immunoblotting for the protein expression of TNF-α (D), cyclooxygenase-2 (Cox-2; E), and nuclear factor-κB (NF-κB) to inhibitor of κB (IκB) ratio (F). Densitometric analyses of protein expression were normalized for protein expression levels of β-actin. Data are mean±SEM for n=10 per group. *P<0.05 compared with insulin-sensitive subjects; #P<0.05 between control and lipopolysaccharide treatment of the same group.
in the intestine of insulin-resistant compared with insulinsensitive subjects ( Figure 4C ). The total expression levels of 5′-adenosine monophosphate-activated protein kinase α and acetyl-CoA carboxylase were not altered in the intestine of insulin-resistant subjects ( Figure 4B and 4D). Concomitantly, [1-14 C]-acetate incorporation into the lipids was higher in the intestinal explants from insulin-resistant compared with insulin-sensitive subjects ( Figure 4E ). These results suggest a higher intestinal de novo lipogenesis rate in the presence of IR. Apo B-48 biogenesis, as tested by [ 35 S]-methionine incorporation, was significantly increased in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 4F ). Furthermore, the use of [ 14 C]-oleic acid as a precursor revealed the presence of a significantly enhanced assembly and secretion of TRL by intestinal explants from insulin-resistant subjects ( Figure 4G ). Overall, these observations suggest that IR stimulates intestinal lipid metabolism by enhancing de novo lipogenesis and Apo B-48 biogenesis, which may collectively contribute to exaggerated TRL synthesis and secretion observed in insulin-resistant subjects. It was important to ensure that intestinal explants from insulin-sensitive and insulin-resistant subjects were similarly viable and metabolically active at the end of the incubation period. Thus, we tested various parameters related to cell proliferation ([ 3 H]-thymidine incorporation), differentiation (sucrase), function (lactase, maltase), glucose metabolism (uptake and oxidation of glucose), cell viability, and membrane integrity (leakage of lactate dehydrogenase and alkaline phosphatase to the medium; Table II in the online-only Data Supplement). No differences were noted between the 2 groups of subjects.
Intestinal Markers of Lipid Metabolism
To assess the mechanisms involved in amplified TRL assembly and secretion, we measured the expression level of key proteins involved in intracellular lipid transport and metabolism. Liver fatty acid-binding protein (L-FABP) and intestinal (I) FABP contents were greater in insulin-resistant compared with insulin-sensitive subjects ( Figure 5A and 5B ). Higher expression levels of microsomal triglyceride transfer protein (MTP), a protein involved in the initial lipid transfer step onto Apo B-48 molecules, were also observed in obese subjects with IR ( Figure 5C ). However, the expression of SAR1 homolog B GTPase, which facilitates the intracellular transport of nascent chylomicron particles from the endoplasmic reticulum to the Golgi apparatus for packaging completion, remained unchanged ( Figure 5D ). These findings suggest that the intestine of insulin-resistant subjects has an increased capacity to transport lipids and to produce TRL compared with the intestine of insulin-sensitive subjects. In addition, our data strengthen the hypothesis that fresh intestinal explants from insulin-resistant subjects have a higher capacity to produce TRL compared with explants from insulin-sensitive subjects.
Intestinal Cholesterol Metabolism
We examined the expression of genes involved in cholesterol metabolism to assess the intestinal involvement in the altered cholesterol phenotype observed in insulin-resistant subjects ( Table 2 ). The protein amount of most cholesterol transporters (ie, NPC1L1, SR-B1, ABCG5, and ABCG8) seemed unchanged in the intestine of both groups of subjects. In contrast, we observed reduced ATP-binding cassette A1 transporter (ABCA1) mRNA expression in the intestine of insulin-resistant compared with insulin-sensitive subjects ( Figure 6A ). Importantly, this transporter mediates intestinal cholesterol efflux and is essential to the formation of HDL. 20 Intestinal mRNA expression of cholesteryl ester transfer protein (CETP), a negative modulator of HDL-cholesterol, remained unchanged between insulin-sensitive and insulin-resistant subjects ( Figure 6B ). The reduced intestinal protein content of proprotein convertase subtilisin/ kexin type 9 (PCSK9), involved in LDL receptor recycling, was also found in insulin-resistant compared with insulin-sensitive subjects ( Figure 6C ). 21, 22 Finally, we found lower levels of the activated form of sterol regulatory element-binding protein 2 in the intestine of insulin-resistant subjects ( Figure 6D ). This latter factor is known to regulate the expression of genes maintaining cholesterol metabolism. Taken together, these results suggest that the intestine of insulin-resistant subjects seems to have a higher capacity to capture circulating LDL-cholesterol and a lower potential to released cholesterol into nascent HDL particles.
Discussion
If obesity and T2D are among the most important scourges of the 21st century, the common underlying driver seems to be IR, which is a prime etiologic factor for dyslipidemia and CVD. 23 In fact, obesity has been proposed to predate and promote IR molecular defect(s), although this assumption has not been proven in humans and was not addressed particularly in the small intestine. Another important issue to clarify is whether a postreceptor defect, which reduces insulin sensing of the classical organs (including skeletal muscle, adipose tissue, and liver), 24, 25 is related to oxidative stress and inflammation potentially residing in the gut of obese subjects. The final impetus consists in defining whether the combination of the aforementioned abnormal processes contributes to intestinal TRL overproduction and abnormal cholesterol metabolism. These puzzling and interesting hypotheses were tested by taking advantage of bariatric surgery, which offered us a unique opportunity to obtain fresh human intestinal specimens. The present experiments show that the duodenal tissue of patients with systemic IR was endowed with shabby insulin sensitivity as assessed by low protein phosphorylation of protein kinase B but high protein phosphorylation of p38 mitogen-activated protein kinase. The presence of oxidative stress was evidenced by increased malondyaldehyde and conjugated diene levels, whereas the occurrence of inflammatory processes was highlighted by the sharp rise in intercellular adhesion molecule-1, cyclooxygenase-2, tumor necrosis factor-α, and interleukin-6 levels as well as in NF-κB activation. Impaired insulin sensitivity along with oxidative stress and inflammation likely impinge on lipid homeostasis as evidenced by the exaggerated lipogenesis and increased TRL assembly probably triggered by the stimulation of expression of I-FABP, L-FABP, Apo B-48, and MTP. The intestinal mucosa of insulinresistant subjects also showed abnormalities in the expression of genes involved in cholesterol metabolism (ABCA1, PCSK9, sterol regulatory element-binding protein 2), suggesting that the gut may play a key role in the altered cholesterol phenotype observed in the presence of systemic IR. These results suggest that the small intestine could be classified as an insulin-sensitive tissue that may become resilient to insulin action in adverse metabolic conditions. Whereas, reduced insulin signaling, conceivably triggered by oxidative stress and inflammation, may prompt an exacerbated lipid and lipoprotein synthesis as well as an abnormal cholesterol profile and could, therefore, contribute to atherogenic dyslipidemia observed in subjects with metabolic syndrome and T2D.
Intriguingly, little attention has been paid to the role that human intestine could play in cardiometabolic disorders, though several observations allude to its active implication as a valuable actor equipped with insulin signaling/sensitivity and redox-inflammatory synergy. The intestine is the target of insulin for the modulation of uptake of various nutrients such as glucose, amino acids, vitamins, and ions. 26 Lipid transport in the enterocyte is also regulated by insulin. 9, 27, 28 The importance of insulin action on the gut has been illustrated by functional alterations present in animals with drug-induced T2D, [29] [30] [31] which also display enhanced intestinal absorption of several nutrients, including glucose and amino acids, 29, 30 as well as increased mucosal mass. 31, 32 Many of these alterations can be restored to control levels by the administration of insulin. 29, 32 Even so, intestinal insulin sensitivity was seldom assessed in normal and pathophysiological conditions. This situation is even more peculiar when one considers that the gut (1) is being recognized as an endocrine organ 33 ; (2) is associated with a significant improvement/remission in T2D when duodenal and jejunal sections are excised 34, 35 ; (3) participates actively in postprandial hyperlipidemia for the majority of the day, in which the enterocyte-derived TRL and chylomicron remnant have a central input 36, 37 by affecting the cells of the artery wall via lipid deposition, 38, 39 oxidative and inflammatory actions, 3, 40 apoptotic/toxic effects, 41 and in the reduction of insulin sensitivity of other organs 42, 43 ; and (4) may develop aberrant insulin receptor signaling at the level of the enterocyte. 15 Free radicals, generated under physiological conditions, play important beneficial roles in human physiology, including their actions as signaling molecules in a variety of cell signaling pathways, and often as second messengers. 44 Similarly, inflammation is another integral aspect of homeostatic regulation that can exert estimable effects against deleterious stimuli, thereby promoting the attenuation of stressors and facilitating the healing process. However, when in excess, the redox and inflammatory processes crosspromote one another in a feed forward cycle, which may play an important role in the development and progression of the metabolic syndrome. 45 In the present study, there was a significant elevation of oxidative stress as evidenced by the markers of lipid peroxidation (malondyaldehyde, conjugated dienes), which probably surpasses the capacity of antioxidant defenses to detoxify them (given the decline in superoxide dismutase activity) in the small intestine of insulin-resistant subjects. Nevertheless, other antioxidant defense markers (catalase and gluthatione peroxydase) remain within normal values, purporting that oxidative stress was not of large amplitude. Alternatively, other antioxidants participated in reactive oxygen species scavenging.
Because an increase in oxidative stress-derived inflammation has been hypothesized to be a major mechanism in the pathogenesis and progression of obesity-related disorders, 46 we examined the inflammatory markers and detected a rise in NF-κB activation in the intestinal specimens of obese patients with systemic IR. This observation was strengthened by the fact that several downstream inflammatory mediators and cytokines regulated by this specific pathway [47] [48] [49] (ie, intercellular adhesion molecule, interleukin-6, tumor necrosis factor-α, and cyclooxygenase-2) were induced in the intestine of insulin-resistant subjects. These findings emphasize that metabolic conditions/stimuli induced the degradation of cytosolic inhibitor of κB with the ensuing translocation of NF-κB to the nucleus, which transcriptionally modulates the cellular genes implicated in inflammatory responses in the gut of insulin-resistant subjects. Collectively, these data indicate that the oxidative stress machinery and inflammatory signaling are not only interrelated but their impairment can lead to an inhibition of insulin responses as well as a higher risk of CVD and associated features in the small intestine of insulin-resistant obese patients. 46, 50 Currently, it is difficult to establish the temporal sequence of the complex and intimate relationship between increased oxidative stress and enhanced inflammation.
To our knowledge, we are the first group to report clear evidence of metabolic alterations in the small intestine of humans with systemic IR. Our results are generally in agreement with those obtained in previous studies performed in animal models with genetic and environment-induced obesity. Alongside the well-established role of the liver in the development of atherogenic dyslipidemia, our findings suggest that intestinal TRL overproduction play a key role in this pathology as shown in animal models. [6] [7] [8] [10] [11] [12] [13] [14] [15] Indeed, the presence of an intestinal IR state has been previously suggested in fructose-fed hamster 15 and in Psammomys obesus. 8 The present study points out to the local insulin signaling defects that may alter the physiological regulation of intestinal TRL production in obese insulinresistant subjects. 15 The overproduction of intestinal TRL may be a consequence of (1) higher intracellular fatty acid transport capacity by I-FABP and L-FABP, (2) increased de novo lipogenesis rates through higher acetyl-CoA carboxylase activation, (3) increased Apo B-48 biogenesis, and (4) enhanced Apo B-48 lipidation capacity by MTP. The present results and conclusions are strongly supported by the findings of increased de novo lipogenesis rate, increased expression of L-FABP, higher abundance of MTP protein expression, and reduced proteasomal degradation of Apo B-48 in the small intestine of insulin-resistant animals. 6, 8 Therefore, the present study presents possible mechanisms filling the gap between human in vivo observation [17] [18] [19] and the detailed characterization of intestinal metabolism performed in animal models of IR. [6] [7] [8] [10] [11] [12] [13] [14] [15] In addition to these defects related to lipid metabolism and TRL production, we reported several molecular alterations indicating the presence of an aberrant intestinal cholesterol metabolism. We first analyzed the expression of apical cholesterol transporters (NPC1L1, ABCG5, and ABCG8) but could not detect any significant alterations, suggesting a similar capacity of the enterocyte to absorb luminal cholesterol in obese individuals with IR. In addition, the examination of ABCA1 located at the basolateral membrane showed a reduced expression, suggesting the low ability to effux cholesterol to nascent HDL, which may explain the low levels of HDL-cholesterol in the plasma of insulin-resistant subjects.
Lower HDL-cholesterol has been described in several insulin-resistant or diabetic populations and has been recognized as an independent risk factor for CVD. 51 Several studies have also reported the triglyceride enrichment of HDL, as a key mechanism leading to reduced HDL levels, in insulin-resistant and T2D patients. 13 In fact, increased CETP in blood circulation enhanced the transfer of triglyceride from TRL to HDL and cholesterol esters from HDL particles to TRL. As a consequence, HDL triglyceride hydrolysis is accelerated and the resulting small and dense HDL particles are more rapidly cleared from blood circulation. 52 Because the small intestine is known as an important contributor to circulating CETP, we tested the intestinal mRNA content of CETP in the 2 groups of obese subjects and did not observe differences. Therefore, the modulation of CETP in the gut is not implicated in the mechanisms that lower HDL-cholesterol levels in insulin-resistant obese individuals. It seems more plausible that the intestine is linked to this phenotype through the low intestinal ABCA1 expression.
In the present investigation, we also focused on PCSK9, a protease that postrancriptionally enhances LDL receptor degradation, thereby regulating the level of LDL-cholesterol in blood circulation. 53 Conversely, the inactivation of PCSK9 enhances the number of LDL receptor molecules on the cell surface and accelerates the clearance of circulating LDL-cholesterol. 54 Although most of the studies have emphasized the central role of PCSK9 in liver cholesterol metabolism, growing evidence documents similar PCSK9 actions in the small intestine. 21 Although PCSK9 protein expression is strongly downregulated by high cholesterol concentrations and diabetes mellitus induction in the 2 organs, 22,55,56 the circulating levels of PCSK9 were not altered in the presence of systemic IR and T2D. 57 In the present investigation, PCSK9 expression was reduced in the intestine of insulin-resistant subjects, which is in line with diabetic data previously reported. However, additional investigation is absolutely required given the growing evidence related to the activation of the assembly of TRL synthesis in the liver and intestine. 21, 58 Using the present methodological approach, we can only associate the overall capacity of the intestine to transport lipids and to produce TRL with the presence of IR independent of the influence of luminal lipid composition. This represents a strength of our study because we directly assessed the impact of local IR on intestinal metabolism without the interference of lipid composition. However, the experimental approach constitutes a limitation because the impact of lipid composition may represent a major determinant of lipid metabolism in insulin-resistant subjects. A detailed food assessment was not available for these subjects, but we observed some differences in plasma fatty acid composition measured by gas chromatography. The results showed increased total fatty acid concentrations as well as elevated saturated fatty acid proportion with reduced percentage of polyunsaturated fatty acids, which may expose the intestinal tissue to inadequate fatty acid pattern and may thus exacerbate inflammation, oxidative stress, and lipid metabolism in the gut. More studies are required to analyze the composition of fatty acids in the intestinal tissues of insulin-resistant obese subjects.
The insulin-sensitive versus insulin-resistant subjects who participated in the present investigation were paired for age, sex, and BMI. However, we acknowledge some limitations of the study, including its cross-sectional design that prevented inference about a cause-and-effect relationship between the presence of intestinal IR, oxidative stress, chronic low-grade inflammation, and development of metabolic alterations leading to intestinal overproduction of TRL in insulin-resistant subjects. The difficulty in obtaining intestinal tissue from these subjects limited our capacity to perform a longitudinal study and to definitively conclude on the chronology of intestinal versus systemic metabolic dysregulation. Future studies are needed to deeply investigate the impact of intestinal IR on cholesterol and lipid metabolism in humans. A direct induction of IR in fresh biopsies from insulin-sensitive subjects could be a possible approach to test this issue.
In conclusion, we demonstrated that the human small intestine should be considered an insulin-sensitive tissue that can be deregulated by the occurrence of local oxidative stress and inflammation. These alterations are likely associated with a pronounced increase in lipid synthesis and Apo B-48 biogenesis as well as with an increased TRL assembly and secretion. These observations point out to the potential mechanisms that link small intestine metabolism to the development of atherogenic dyslipidemia commonly observed in subjects with metabolic syndrome and T2D. Further studies are needed to better define the role of small intestine in atherogenic dyslipidemia because it may help in identifying new therapeutic strategies to reduce CVD risk in insulin-resistant and diabetic patients. thank Marie-Claude Denis (Department of Nutrition, CHU Sainte Justine, Montréal, Québec, Canada) for her assistance in malondyaldehyde quantification, and Dr Benoît Lamarche (Nutraceuticals and Functional Food Institute, Laval University, Québec) for his assistance in LDL size measurement. We also thank Schohraya Spahis (Department of Nutrition, CHU Sainte-Justine) for her technical assistance.
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